Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites

This publication has 18 references indexed in Scilit:

• Metabolic polymorphisms
  Pharmacology & Therapeutics, 1993
• Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast
  Biochemical Pharmacology, 1992
• Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers
  Chirality, 1991
• Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae
  Biochemistry, 1990
• Expression of human liver cytochrome P450 IIIA4 in yeast
  European Journal of Biochemistry, 1990
• The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
  Pharmacology & Therapeutics, 1990
• Synthesis of 10, 11-Dihydroxydihydroquinidine N-oxide, a New Metabolite of Quinidine. Preparation and ¹H-nmr Spectroscopy of the Metabolites of Quinine and Quinidine and Conformational Analysis via 2D COSY NMR Spectroscopy
  Journal of Natural Products, 1990
• Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes
  Clinical Pharmacology & Therapeutics, 1988
• Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
  British Journal of Clinical Pharmacology, 1986
• Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
  Life Sciences, 1984